The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer

Modern Pathology

Volumn 23, Issue 2, 2010, Pages 251-259

  Klintman, Marie ^a   Bendahl, Pär Ola ^a   Grabau, Dorthe ^a   Lövgren, Kristina ^a   Malmström, Per ^a   Fernö, Mårten ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Breast cancer; Ki67; Node negative; Premenopausal; Prognostic factor; Proliferation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CELL PROLIFERATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GROUPS BY AGE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; TISSUE MICROARRAY; TUMOR VOLUME;

ADULT; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; KI-67 ANTIGEN; MIDDLE AGED; PREMENOPAUSE; PROGNOSIS; RECEPTORS, ESTROGEN; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 76349123384     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.167     Document Type: Article

References (32)

1. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-5312. (Pubitemid 350232263)
2. Eifel P, Axelson JA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001;93:979-989.
3. Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol 2009;20: 1319-1329.
4. Beresford MJ, Wilson GD, Makris A. Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res 2006;8:216.
5. Colozza M, Azambuja E, Cardoso F, et al. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 2005;16:1723-1739.
6. de Azambuja E, Cardoso F, de Castro Jr G, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007;96:1504-1513.
7. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005;23:7212-7220.
8. Brown DC, Gatter KC. Ki67 protein: the immaculate deception? Histopathology 2002;40:2-11.
9. Malmstrom P, Bendahl PO, Boiesen P, et al. S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. J Clin Oncol 2001;19:2010-2019.
10. Silvestrini R, Daidone MG, Luisi A, et al. Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. J Clin Oncol 1995;13:697-704.
11. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406: 747-752.
12. Ivshina AV, George J, Senko O, et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 2006;66: 10292-10301.
13. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-2826.
14. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-10874.
15. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-536.
16. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;98:262-272.
17. Railo M, Lundin J, Haglund C, et al. Ki-67, p53, ER receptors, ploidy and S phase as long-term prognostic factors in T1 node-negative breast cancer. Tumour Biol 2007;28:45-51.
18. Ahlin C, Aaltonen K, Amini RM, et al. Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values? Histopathology 2007;51: 491-498.
19. Brown RW, Allred CD, Clark GM, et al. Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res 1996;2:585-592.
20. Pinder SE, Wencyk P, Sibbering DM, et al. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 1995;71:146-149.
21. Rudolph P, Alm P, Heidebrecht HJ, et al. Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer. J Natl Cancer Inst 1999;91:271-278.
22. Jung SY, Han W, Lee JW, et al. Ki-67 Expression gives additional prognostic information on St. Gallen 2007 and adjuvant! Online risk categories in early breast cancer. Ann Surg Oncol 2009;16:1112-1121.
23. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-410.
24. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 1982;69:239-241.
25. Teschendorff AE, Miremadi A, Pinder SE, et al. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 2007;8:R157.
26. Harvey JM, de Klerk NH, Sterrett GF. Histological grading in breast cancer: interobserver agreement, and relation to other prognostic factors including ploidy. Pathology 1992;24:63-68.
27. Boiesen P, Bendahl PO, Anagnostaki L, et al. Histologic grading in breast cancer-reproducibility between seven pathologic departments. South Sweden Breast Cancer Group. Acta Oncol 2000;39:41-45.
28. Hilsenbeck SG, Ravdin PM, de Moor CA, et al. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 1998;52:227-237.
29. Railo M, Lundin J, Haglund C, et al. Ki-67, p53, Er-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer. Acta Oncol 1997;36:369-374.
30. Spyratos F, Ferrero-Pous M, Trassard M, et al. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer 2002;94:2151-2159.
31. Nocito A, Bubendorf L, Tinner EM, et al. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 2001;194:349-357.
32. Ruiz C, Seibt S, Al Kuraya K, et al. Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. Int J Cancer 2006;118: 2190-2194.